Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JBM (Healthcare)HKSE:02161 86 Return-on-Tangible-Equity is 366.16% as of Mar. 2026, which is 255% above its 10-year median of 103.11. GuruFocus rates HKSE:02161 with a GF Score™ of 86/100 and a GF Value™ of HK$2.08 (Fairly Valued). The stock has 4 warning signs investors should review. Among 901 Drug Manufacturers companies, JBM (Healthcare) ranks better than 93.23% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. JBM (Healthcare)'s annualized net income for the quarter that ended in Mar. 2026 was HK$172.2 Mil. JBM (Healthcare)'s average shareholder tangible equity for the quarter that ended in Mar. 2026 was HK$47.0 Mil. Therefore, JBM (Healthcare)'s annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 366.16%.
The historical rank and industry rank for JBM (Healthcare)'s Return-on-Tangible-Equity or its related term are showing as below:
HKSE:02161'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 35.15 Med: 103.11 Max: 169.18
Current: 169.18
During the past 9 years, JBM (Healthcare)'s highest Return-on-Tangible-Equity was 169.18%. The lowest was 35.15%. And the median was 103.11%.
HKSE:02161's Return-on-Tangible-Equity is ranked better than 93.23% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.89
vs HKSE:02161: 169.18
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
JBM (Healthcare) Return-on-Tangible-Equity Related Terms
JBM (Healthcare) Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for JBM (Healthcare)'s Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02161 vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, JBM (Healthcare)'s Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JBM (Healthcare) Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, JBM (Healthcare)'s Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where JBM (Healthcare)'s Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 366.16% mean?
JBM (Healthcare) (HKSE:02161) has a Return-on-Tangible-Equity of 366.16% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on JBM (Healthcare) and its competitors. This is 255% above median its historical median of 103.11. Over the past decade, JBM (Healthcare)'s Return-on-Tangible-Equity has ranged from 35.15 to 169.18. According to the industry distribution chart, JBM (Healthcare) ranks #61 out of 901 companies in the Drug Manufacturers industry, placing it in the top 6.8%.
Is JBM (Healthcare)'s Return-on-Tangible-Equity too high?
JBM (Healthcare)'s current Return-on-Tangible-Equity of 366.16% is 255% above median its 10-year median of 103.11. Over the past 10 years, this metric has ranged from a low of 35.15 to a high of 169.18. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.89. JBM (Healthcare)'s value of 366.16% is 4540.8% above this industry median. Based on the distribution chart, JBM (Healthcare) ranks #61 out of 901 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, JBM (Healthcare) has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does JBM (Healthcare)'s Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, JBM (Healthcare) ranks #61 out of 901 companies for Return-on-Tangible-Equity. This places JBM (Healthcare) in the top 7% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.89. JBM (Healthcare)'s value of 366.16% is 4540.8% above this benchmark. Historically, JBM (Healthcare)'s own Return-on-Tangible-Equity has ranged from 35.15 to 169.18 over the past decade. While the company's 10-year median is 103.11 vs. the industry median of 7.89, JBM (Healthcare) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.89, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JBM (Healthcare)'s current Return-on-Tangible-Equity of 366.16% is 4540.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on JBM (Healthcare) and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JBM (Healthcare)'s current Return-on-Tangible-Equity is 366.16%, which is 255% above median its own 10-year median of 103.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JBM (Healthcare) stock overvalued right now?
Based on GuruFocus' analysis, JBM (Healthcare) (HKSE:02161) is currently considered Fairly Valued. The stock's GF Value™ is HK$2.08, compared to a current price of HK$1.92 — trading 7.7% below its estimated fair value. The current Return-on-Tangible-Equity is 366.16%, which is 255% above median its 10-year median of 103.11 and 4540.8% above the Drug Manufacturers industry median of 7.89. JBM (Healthcare)'s overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For JBM (Healthcare) (HKSE:02161), the current Return-on-Tangible-Equity is 366.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JBM (Healthcare) (HKSE:02161) Overvalued in 2026?
Based on GuruFocus' analysis, JBM (Healthcare) stock appears to be undervalued.
The current stock price of HK$1.92 is trading 7.7% below its estimated GF Value™ of HK$2.08.
GuruFocus considers JBM (Healthcare) to be Fairly Valued.
Key valuation signals for HKSE:02161:
Return-on-Tangible-Equity: 366.16% (255% above median its 10-year median of 103.11)
GF Value™: HK$2.08 vs. price of HK$1.92 (7.7% below fair value)
Industry Position: 4540.8% above the Drug Manufacturers median (#61 of 901)
No single metric tells the full story. See the HKSE:02161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JBM (Healthcare) Ltd markets and distributes healthcare products. The company's operating segment includes Branded medicines; Proprietary Chinese medicines and Health and wellness products. It generates maximum revenue from the Proprietary Chinese medicines segment. The Proprietary Chinese medicines segment develops, manufactures, and distributes registered Chinese medicines composed solely of any Chinese herbal medicines specified in the Chinese Medicine Ordinance, or any materials of herbal, animal, or mineral origin customarily or widely used by the Chinese. Geographically, it derives a majority of its revenue from Hong Kong.
86GF Score
Get the complete analysis for HKSE:02161
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02161 has been successfully added to your 
